Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus. Motif Bio plc was incorporated in 2014 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MTFB
CUSIPN/A
Phone212-210-6248
Debt
Debt-to-Equity Ratio-1.58
Current Ratio0.96
Quick Ratio0.96
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.68) per share
Price / Book-13.88
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees6
Outstanding Shares14,830,000
Motif (NASDAQ:MTFB) Frequently Asked Questions
What is Motif's stock symbol?
Motif trades on the NASDAQ under the ticker symbol "MTFB."
What price target have analysts set for MTFB?
5 equities research analysts have issued 12-month target prices for Motif's stock. Their forecasts range from $7.00 to $32.00. On average, they anticipate Motif's stock price to reach $19.50 in the next twelve months. View Analyst Ratings for Motif.
What are Wall Street analysts saying about Motif stock?
Here are some recent quotes from research analysts about Motif stock:
- 1. HC Wainwright analysts commented, "We reiterate our Buy rating and 12-month target of $32.00 per share on MTFB." (6/11/2018)
- 2. WBB Securities analysts commented, "We believe there is a critical need for novel antibiotics. Based on the clinical data provided through Phase 3 studies REVIVE-1 and REVIVE-2, iclaprim has a high probability of obtaining FDA approval. However, success for MTFB is not just manifest through clinical proof, but also through negotiating the vagaries of reimbursement, gaining clinician acceptance, hospital inclusion and inclusion in the overall patient care paradigm. Additionally, we remain concerned about the resourcing path regarding the future of iclaprim. We are therefore initiating our coverage of MTFB with a Sell rating and a 12- month price target of $7.00." (12/29/2017)
Who are some of Motif's key competitors?
Some companies that are related to Motif include Achaogen (AKAO), Cara Therapeutics (CARA), Obseva (OBSV), Viking Therapeutics (VKTX), TIGENIX/S (TIG), Lannett (LCI), AC Immune (ACIU), Rigel Pharmaceuticals (RIGL), Stemline Therapeutics (STML), Zymeworks (ZYME), Merus (MRUS), Aurinia Pharmaceuticals (AUPH), Synergy Pharmaceuticals (SGYP), ZIOPHARM Oncology (ZIOP) and Depomed (DEPO).
Who are Motif's key executives?
Motif's management team includes the folowing people:
- Mr. Graham George Lumsden, CEO & Exec. Director (Age 58)
- Mr. Jonathan E. Gold, Interim CFO, Strategic Financial Consultant & Non-Exec. Director (Age 45)
- Mr. Robert Joseph Bertoldi, Exec. Director (Age 64)
- Dr. David B. Huang M.D., Ph.D., MBA, J.D., Chief Medical Officer (Age 43)
- Mr. Robert Dickey IV, Advisor (Age 62)
When did Motif IPO?
(MTFB) raised $17 million in an IPO on Friday, November 18th 2016. The company issued 2,400,000 shares at a price of $6.98 per share. H.C. Wainwright & Co. served as the underwriter for the IPO.
Has Motif been receiving favorable news coverage?
Press coverage about MTFB stock has been trending somewhat negative recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Motif earned a media sentiment score of -0.02 on Accern's scale. They also assigned media coverage about the company an impact score of 44.30 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Motif?
Shares of MTFB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Motif's stock price today?
One share of MTFB stock can currently be purchased for approximately $9.44.
How big of a company is Motif?
Motif has a market capitalization of $139.97 million. The company earns $-44,810,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Motif employs 6 workers across the globe.
How can I contact Motif?
Motif's mailing address is 125 Park Avenue 25th Floor, New York NY, 10011. The company can be reached via phone at 212-210-6248 or via email at [email protected]
MarketBeat Community Rating for Motif (MTFB)
MarketBeat's community ratings are surveys of what our community members think about Motif and other stocks. Vote "Outperform" if you believe MTFB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTFB will underperform the S&P 500 over the long term. You may vote once every thirty days.
